These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 9664930)

  • 21. Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue.
    den Boer MA; Berbée JF; Reiss P; van der Valk M; Voshol PJ; Kuipers F; Havekes LM; Rensen PC; Romijn JA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):124-9. PubMed ID: 16269669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
    Guivarc'h PH; Vachon MG; Fordyce D
    Clin Ther; 2004 Sep; 26(9):1456-69. PubMed ID: 15531008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
    Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates.
    Cicero AF; Derosa G; Miconi A; Laghi L; Nascetti S; Gaddi A
    Biomed Pharmacother; 2005 Jul; 59(6):312-7. PubMed ID: 15932792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.
    Carmona MC; Louche K; Nibbelink M; Prunet B; Bross A; Desbazeille M; Dacquet C; Renard P; Casteilla L; Pénicaud L
    Int J Obes (Lond); 2005 Jul; 29(7):864-71. PubMed ID: 15917863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertriglyceridemia and its pharmacologic treatment among US adults.
    Ford ES; Li C; Zhao G; Pearson WS; Mokdad AH
    Arch Intern Med; 2009 Mar; 169(6):572-8. PubMed ID: 19307519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [On the article by Dr. R. Ceska, et al: Fenofibrat Pharmavit SR 250 in patients with mixed hyperlipoproteinemia].
    Mayer O
    Cas Lek Cesk; 2001 Mar; 140(6):188-9. PubMed ID: 11347210
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
    McKenney JM; Sica D
    Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapy effects of fenofibrate on alcoholic fatty liver and drug-induced fatty liver in rats].
    Yan M; Meng FL; Lu RJ; Jia XQ; Zhao XC
    Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):86-9. PubMed ID: 12648401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.
    Magee G; Sharpe PC
    J Clin Pathol; 2009 Mar; 62(3):250-3. PubMed ID: 19251953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of micronized fenofibrate on vascular endothelial function in patients with hypertriglyceridemia.
    Huang Y; Dai G; Feng Z; Lu C; Cheng B; Wang Q; Nie F; Li J
    Chin Med J (Engl); 2003 Nov; 116(11):1767-9. PubMed ID: 14642156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
    Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
    Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
    Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
    Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.
    Musolino A; Panebianco M; Zendri E; Santini M; Di Nuzzo S; Ardizzoni A
    Br J Haematol; 2009 Apr; 145(1):84-6. PubMed ID: 19208096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy and clinical trials.
    Usman M; Peter R
    Curr Opin Lipidol; 2006 Oct; 17(5):612-4. PubMed ID: 16960511
    [No Abstract]   [Full Text] [Related]  

  • 39. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
    Davidson MH
    Expert Opin Drug Saf; 2006 Jan; 5(1):145-56. PubMed ID: 16370963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fenofibrate-induced photosensitivity.
    Leenutaphong V; Manuskiatti W
    J Am Acad Dermatol; 1996 Nov; 35(5 Pt 1):775-7. PubMed ID: 8912578
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.